Taken together, these data demonstrate that genetic inhibition of novel-miR-7 is capable of neutralizing microvascular endothelial hyperpermeability induced by NAFLD hepatic sEVs through regulating the LAMP1/Cathepsin B/NLRP3 inflammasome axis. Here, CTSB is linked to metabolic dysfunction-associated steatotic liver disease.